Anti-Podoplanin Rabbit Polyclonal Antibody for WB, IHC-P, ELISA - Q86YL7

Core Product Specifications and Parameters

Biological Background: Podoplanin Function and Localization

• Podoplanin (PDPN, also known as Aggrus, GP36, T1A) is a type I transmembrane glycoprotein with extracellular, transmembrane, and cytoplasmic domains. It undergoes alternative splicing and is heavily sialylated.
• Through binding to CLEC1B, podoplanin triggers platelet activation and aggregation, key to blood/lymphatic vessel separation (PubMed:14522983, PubMed:15231832, PubMed:17222411). Interaction with CD9 attenuates this aggregation (PubMed:18541721). Related references: PMID:14522983 PMID:15231832 PMID:17222411 PMID:18541721
• Interaction with MSN or EZR promotes epithelial-mesenchymal transition (EMT), leading to ERZ phosphorylation and RHOA activation, thereby enhancing cell migration and invasiveness (PubMed:17046996, PubMed:21376833). Related references: PMID:17046996 PMID:21376833
• Podoplanin binding to CD44 promotes directional cell migration in epithelial and tumor cells (PubMed:20962267). It also controls invadopodia stability and extracellular matrix degradation via the RHOC-ROCK-LIMK-CFL1 pathway (PubMed:25486435). Related references: PMID:20962267 PMID:25486435
• In lymph nodes, podoplanin regulates fibroblastic reticular cell adhesion and contractility through ERM proteins and MYL9 activation; CLEC1B engagement induces relaxation (By similarity).
• Podoplanin localizes primarily to the plasma membrane and is enriched in membrane projections: lamellipodia, filopodia, microvilli, ruffles, and invadopodia. It also traffics to membrane rafts and shows apical/basolateral polarity.
• Highly expressed in placenta, lung, skeletal muscle, and brain; upregulated in colorectal tumors and some oral squamous cell carcinomas.
• In keratinocytes, podoplanin expression leads to elongated morphology, actin cytoskeleton reorganization, increased motility, and decreased cell adhesion (PubMed:15515019). Related references: PMID:15515019

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 23-131, a region within the extracellular domain; this design likely targets epitopes accessible in native and denatured conditions, supporting WB and IHC-P applications.
• For WB, the predicted molecular weight is ~17 kDa; however, extensive O-glycosylation and sialylation may cause bands to appear at 36–44 kDa or higher under reducing conditions. Validate using appropriate positive controls such as lung or placenta lysates.
• For IHC-P, consider antigen retrieval and validate staining in known positive tissues (e.g., placenta, lung, tumor sections) with appropriate negative controls.
• Cross-reactivity with mouse and rat has been indicated; however, verify sequence homology and expected band sizes across species before use in multi-species experiments.
• For ELISA, the recombinant immunogen can serve as a capture standard; test coating conditions and ensure detection antibody compatibility.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting covering every stage from concept to clinic. For podoplanin research in tumor migration, cardiovascular biology, and lymphatic development, we offer validated antibody pairs, bulk ancillary reagents, and customized raw-material sourcing. Contact us to streamline your assay development and procurement needs.